Catalyst Pharmaceuticals, INC

Catalyst Pharmaceuticals announced that its stockholders have approved the merger agreement with Angelini Pharma, paving the way for the acquisition.

Catalyst Pharmaceuticals announced topline results from a Phase 1 study of vamorolone, indicating on-target glucocorticoid activity without significant immunosuppression at clinical doses.

Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1 billion in cash, a move that marks Angelini's entry into the U.S. market and strengthens its rare disease and brain health focus.

Catalyst Pharmaceuticals reported record full-year 2025 revenues of $589.0 million, a 19.8% year-over-year increase, and provided 2026 revenue guidance of $615 million to $645 million.

Catalyst Pharmaceuticals increased its full-year 2025 revenue guidance, driven by strong performance in its rare disease portfolio and a robust acquisition strategy.

Catalyst Pharmaceuticals reported strong third-quarter 2025 financial results, with total revenues of $148.4 million, and raised its full-year 2025 total revenue guidance to between $565 million and $585 million.

Catalyst Pharmaceuticals reports strong third-quarter and nine-month financial results, driven by robust sales of FIRDAPSE and AGAMREE, despite generic competition impacting FYCOMPA.

Catalyst Pharmaceuticals reports significant revenue and net income growth in Q2 2025, driven by strong performance of FIRDAPSE and AGAMREE, despite anticipated generic competition for FYCOMPA.

Catalyst Pharmaceuticals announces a significant increase in revenue and net income for the first quarter of 2025, driven by strong sales performance across its product portfolio.

Catalyst Pharmaceuticals' Q3 2024 results show significant revenue growth and profitability, driven by increased sales of FIRDAPSE, FYCOMPA, and AGAMREE.

Catalyst Pharmaceuticals saw a significant increase in revenue and cash reserves in the second quarter of 2024, driven by strong sales of its three key products.

Catalyst Pharmaceuticals' first quarter 2024 results show a 15% increase in revenue compared to the same period last year, driven by sales of FIRDAPSE, FYCOMPA and the launch of AGAMREE.

Catalyst Pharmaceuticals, Inc. filed an amendment to its 2025 Annual Report to include required governance and executive compensation disclosures.

Catalyst Pharmaceuticals reported significant revenue and net income growth in its 2025 annual report, primarily fueled by the successful commercialization of AGAMREE and continued FIRDAPSE sales, despite generic competition for FYCOMPA.

Catalyst Pharmaceuticals' 2024 10-K filing highlights increased revenue driven by FIRDAPSE and AGAMREE, while addressing ongoing patent litigation and strategic portfolio expansion.

Catalyst Pharmaceuticals has detailed its executive severance and change in control plan, outlining benefits for senior management upon termination or change in control.

Brian Elsbernd, Chief Legal Officer of Catalyst Pharmaceuticals, Inc., reported multiple transactions in common stock on July 15, 2026.

Daniel J. Curran, a Director of Catalyst Pharmaceuticals, Inc., reported multiple transactions in common stock on July 15, 2026.

David S Tierney, a Director of Catalyst Pharmaceuticals, Inc., reported multiple transactions in common stock on July 15, 2026.

Steve Miller, Chief Op. & Scientific Officer of Catalyst Pharmaceuticals, Inc., reported multiple transactions in common stock on July 15, 2026.

Tamar Thompson, a Director of Catalyst Pharmaceuticals, Inc., reported multiple transactions in common stock on July 15, 2026.

Gregg Russo, Chief HR Officer of Catalyst Pharmaceuticals, Inc., reported multiple transactions in common stock on July 15, 2026.

Catalyst Pharmaceuticals is holding its 2025 Annual Meeting of Stockholders on May 20, 2025, to vote on key proposals including the election of directors, an amendment to the 2018 Stock Incentive Plan, executive compensation, and the ratification of its independent auditor.

Catalyst Pharmaceuticals is holding its annual meeting to elect directors, approve an amendment to its stock incentive plan, provide advisory approval of executive compensation, and ratify its accounting firm.

The Vanguard Group has reported a 0% beneficial ownership in Catalyst Pharmaceuticals Inc. following an internal realignment.

State Street Corporation has reported a 5.2% beneficial ownership stake in Catalyst Pharmaceuticals Inc. common stock as of September 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 13.9% of Catalyst Pharmaceuticals, Inc.'s common stock as of March 31, 2025.

Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., and James E. Flynn have jointly filed an amendment to their Schedule 13G, disclosing a continued passive beneficial ownership of 2.63% in Catalyst Pharmaceuticals, Inc.